[Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure].
The study aimed to assess the influence of long-term rhu-EPO treatment on secretion of pancreatic polypeptide (PP) and gastrin. A total of 27 haemodialysed patients and nine healthy subjects were examined. Nine patients with uraemic anaemia were treated with rhu-EPO for 12 months (EPO group), while another nine patients did not receive rhu-EPO (non-EPO group), but were monitored biochemically and clinically as patients of the EPO group. The third group (HD) comparised nine haemodialysed patients with a haematocrit value > or = 30% without rhu-EPO therapy. In all subjects plasma levels of PP and gastrin were estimated before and after administration of a test meal. Patients of the EPO and non-EPO group were examined before and after 6 and 12 months of rhu-EPO therapy (EPO group) or clinical monitoring (non-EPO group) respectively, while only one test was performed in patients of the HD group and healthy subjects. Six months rhu-EPO therapy was followed by an decrease of basal plasma level of PP and increased response of gastrin to the test meal. After 12 months of rhu-EPO therapy basal plasma level of PP was still lower, the response of PP secretion to a test meal was higher, while that of gastrin secretion lower that the pretreatment ones. Our results suggest, that rhu-EPO treatment exerts effect on secretion of PP and gastrin. These alterations seem not to be related to improvement of the haematological status.
Nieszporek
T
T
Katedry i Kliniki Nefrologii Sl.AM w Katowicach.
Kokot
F
F
Wiecek
A
A
Marcinkowski
W
W
Rudka
R
R
Trembecki
J
J
D000328:Adult; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005755:Gastrins / Q000097:blood / Q000187:drug effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008875:Middle Aged; D010191:Pancreatic Polypeptide / Q000097:blood / Q000187:drug effects*; D011994:Recombinant Proteins; D006435:Renal Dialysis
D005755:Gastrins; D011994:Recombinant Proteins; D004921:Erythropoietin; D010191:Pancreatic Polypeptide